Welcome to our dedicated page for Orexo Ab news (Ticker: ORXOY), a resource for investors and traders seeking the latest updates and insights on Orexo Ab stock.
Orexo AB (ORXOY) is a Swedish pharmaceutical innovator specializing in advanced drug-delivery systems and treatments for opioid use disorder, overdose reversal, and allergic emergencies. This page aggregates official company announcements, clinical trial updates, and strategic financial developments.
Investors and industry professionals will find timely updates on Orexo’s proprietary AmorphOX technology, regulatory milestones, and social bond issuances. Key content includes earnings reports, partnership announcements, patent extensions, and progress on high-priority therapies like OX124 (naloxone) and OX640 (epinephrine).
All updates are sourced directly from Orexo’s communications and verified third-party coverage. Bookmark this page to monitor the company’s progress in addressing critical healthcare challenges through pharmaceutical innovation and sustainable financing strategies.
Orexo reported its Q1 2023 financial results, with net revenues of SEK 158.8 million, slightly down from SEK 159.4 million in Q1 2022. The company experienced a significant EBITDA decline, reporting SEK -41.1 million compared to SEK 2.8 million last year. Net earnings also saw a loss of SEK -63.9 million, worse than the previous SEK -23.6 million. Despite stable ZUBSOLV® sales in both SEK and USD, operating expenses surged by 30.6%, totaling SEK 189.4 million. A New Drug Application for OX124 has been submitted to the FDA, but challenges in the packaging line require a resubmission planned for Q3 2023. Cash flow from operations stood at SEK -61.6 million, with cash reserves down to SEK 278.9 million.
FAQ
What is the current stock price of Orexo Ab (ORXOY)?
What is the market cap of Orexo Ab (ORXOY)?
